Obermatt
See Similar Stocks →

Karyopharm Therapeutics

NSQ:KPTI · US48576U2050
BiotechnologySmall

360° View

6
Price/Sales81
Price/Earnings42
Price/Book74
Dividend Yield1
Revenue Growth19
Profit Growth22
Capital Growth4
TSR 52w84
Leverage1
Liquidity52
Refinancing6
Combined17
Analyst Opinions38
Pro Holdings49
Opinion Changes50
Market Pulse21

Profile

CountryUSA
IndustryBiotechnology
SizeSmall
TypePublic Company
ExchangeNASDAQGS
Founded2008
Employees290
Websitekaryopharm.com
ISINUS48576U2050
Last UpdateApr 2, 2026
Index & Theme
HematologyOncologyNeurologyHealth CareMedicalPharmaceutical

Description

Karyopharm Therapeutics Inc. operates as a commercial-stage pharmaceutical company. The company is pioneering novel cancer therapies and is dedicated to the discovery, development, and commercialization of first-in-class drugs directed against nucle…

Analysis

Karyopharm Therapeutics's 360° View rank of 6 places it among the weakest overall — better than 6% of its true peers.

It's lagging on growth (10) and looks cheap versus peers (85). On safety it is highly leveraged (6), and the market shows skeptical sentiment (23). Taken together, its Combined rank of 17 reads as among the weakest overall.

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
81
—
—
—
Price/Earnings
42
—
—
—
Price/Book
74
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
85
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Karyopharm Therapeutics with its peers
Kura Oncology
NSQ:KURA
30
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Contineum Therapeutics
NSQ:CTNM
80
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Puma Biotechnology
NSQ:PBYI
79
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Krystal Biotech
NSQ:KRYS
96
CountryUSA
IndustryBiotechnology
SizeMedium
Full Stock Analysis →
Opus Genetics
NAQ:IRD
52
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Xeris Pharmaceuticals
NSQ:XERS
70
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →